Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth quantity limits Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Quantity limits — Premium Formulary (Premium Non‑Specialty)

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines quantity limit rules for medications on the AmeriHealth Premium Formulary for pharmacy benefit plans, describing per-drug or per-class limits and guidance for members and providers about covered quantities and plan interactions.

    Policy Summary
    PayerAmeriHealth
    PolicyQuantity limits — Premium Formulary (Premium Non‑Specialty)
    Policy CodePolicy N/A
    Change TypeRoutine update — no material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionDocument whether the patient is new to opioid treatment or experienced on prescriptions so the appropriate per-day quantity limit and short-course duration are applied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipletherapy classes listed
    opioid-specificopioid-specific rules
    time-basedtime-based limits
    Premium Non‑Specialtyformulary tier

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2026-07-01
    effective date

    Coverage Criteria and General Rules

    General quantity limit coverage

    Covered when within specified quantity limits

    Standard coverage condition: A medication listed with a quantity limit is covered up to the stated quantity and time period (e.g., tablets per day, mL per fill or per 28/30/365 days).per‑drug limits as listed

    If quantities exceed listed limits, coverage may be denied or prior authorization required.

    Opioid therapy quantity rules

    Opioid-specific coverage rules

    Opioid new vs experienced: Opioid prescriptions have distinct limits for patients new to opioid treatment versus experienced patients; new patients are generally limited to shorter supplies (commonly up to 7 days) and lower per‑day tablet or mL caps while experienced patients have higher per‑day caps.varies by drug (see product lines)

    Multiple opioid products have individualized limits listed in the formulary.

    Quantity limits by product and patient opioid experience

    Coverage follows preset quantity limits that differ for patients 'new to opioid treatment' versus 'experienced with opioid treatment'.

    Hydrocodone/ibuprofen tablets: If patient is new to opioid treatment: limit to 4–6 tabs/day (commonly) for up to 7 days; if experienced: higher daily limits apply (examples include 9–12 tabs/day depending on product variant).per‑day tab limits; up to 7 days for new starts

    Multiple hydrocodone/ibuprofen strengths referenced with varying experienced‑user caps

    Hydromorphone ER tablets: Typical limit for ER formulations: 2 tablets/day in many entries; some entries reference up to 9 tabs/day for experienced users on certain formulations.2 tabs/day typical; up to 9 tabs/day referenced

    ER formulations and product variants repeated across chunks

    Hydromorphone liquid: If new to opioid treatment: limit to 10 mL/day (1 mg/mL) for up to 7 days; if experienced: limit to 18 mL/day.

    Formulation- and experience-based quantity limits

    Covered when within the following formulation- and experience-based quantity limits

    Hydromorphone suppositories (3 mg): If the patient is new to opioid treatment: limit to 3 suppositories/day for up to 7 days; if experienced: limit up to 6 suppositories/day.3 supps/day (new) or 6 supps/day (experienced)

    Repeated across multiple entries

    Hydromorphone liquid (1 mg/mL): If the patient is new to opioid treatment: limit to 10 mL/day for up to 7 days; if experienced: limit to 18 mL/day.10 mL/day (new, up to 7 days) or 18 mL/day (experienced)

    Conserved across chunks

    Hydromorphone ER tablet: Limit commonly listed as 2 tablets/day for ER formulation; some entries reference up to 9 tablets/day for experienced users or specific formulations.2 tablets/day (typical) or up to 9 tabs/day (limited reference)

    Per‑day quantity limits (initial/short course)

    Quantity limits for hydromorphone formulations are applied based on patient opioid experience and formulation. Covered when the prescription does not exceed the following per‑day limits (as stated):

    Hydromorphone liquid (1 mg/mL): New to opioid treatment: limited to 10 mL/day for up to 7 days; Experienced with opioid treatment: limited to 18 mL/day.10 mL/day (new), 18 mL/day (experienced)

    Appears repeatedly across chunks

    Hydromorphone suppository (3 mg): New to opioid treatment: limited to 3 suppositories/day for up to 7 days; Experienced: limited to 6 suppositories/day.3 supps/day (new), 6 supps/day (experienced)

    Appears repeatedly across chunks

    Hydromorphone tablet (2 mg): Document references a limit of 5 tablets/day for 2 mg tablets for up to 7 days; ER tablet examples also cite 2 tablets/day in some entries.

    Daily quantity limits by formulation and patient opioid experience

    Quantity limits for hydromorphone formulations (applies when dispensing for outpatient, non‑specialty use):

    Hydromorphone liquid 1 mg/mL: If new to opioid treatment: limit 10 mL/day for up to 7 days. If experienced with opioid treatment: limit 18 mL/day.10 mL/day (new) or 18 mL/day (experienced)

    See chunks 72,75

    Hydromorphone suppository 3 mg: If new to opioid treatment: limit 3 suppositories/day for up to 7 days. If experienced with opioid treatment: limit 6 suppositories/day.3 supps/day (new) or 6 supps/day (experienced)

    See chunks 72,74

    Hydromorphone tablet 2 mg: If new to opioid treatment: limit 5 tablets/day for up to 7 days. If experienced with opioid treatment: limit generally shown as up to 9 tablets/day in several entries.5 tabs/day (new) or up to 9 tabs/day (experienced)

    Formulation-specific short-term quantity limits

    Quantity limits apply when prescriptions are filled for hydromorphone formulations; limits differ by formulation and whether patient is new or experienced with opioid treatment.

    Hydromorphone oral solution: Limited to 10 mL/day for up to 7 days for new users; limited to 18 mL/day for experienced users.10 mL/day (new) or 18 mL/day (experienced)

    chunks 90,98

    Hydromorphone suppository 3 mg: Limited to 3 suppositories/day for up to 7 days for new users; limited to 6 suppositories/day for experienced users.3 supps/day (new) or 6 supps/day (experienced)

    chunks 90,98

    Hydromorphone tablets 2 mg: Limited to 5 tablets/day for up to 7 days for new users; limited to 9 tablets/day for experienced users.5 tabs/day (new) or 9 tabs/day (experienced)

    Quantity limits by formulation and patient opioid experience

    Coverage is allowed when prescription quantities conform to these per‑formulation limits (distinguishing opioid‑naïve vs experienced patients):

    Hydromorphone suppository 3 mg: If patient is new to opioid treatment: limited to 3 suppositories/day for up to 7 days; if experienced: limited to 6 suppositories/day.3 supps/day (new) | 6 supps/day (experienced)

    chunks 108,112,121

    Hydromorphone tablet 2 mg: If patient is new to opioid treatment: limited to 5 tablets/day for up to 7 days; if experienced: limited to 9 tablets/day.5 tabs/day (new) | 9 tabs/day (experienced)

    chunks 108,112,117

    Hydromorphone tablet 4 mg: If patient is new to opioid treatment: limited to 2 tablets/day for up to 7 days; if experienced: limits referenced variably (examples up to 4 tabs/day in some lines).

    Product‑specific quantity limit rule

    Quantity limits applied per product depending on patient opioid experience

    General rule: For each listed opioid product, apply the per‑day quantity limit shown. Limits differ depending on whether the patient is new to opioid treatment or experienced; new patients typically limited to shorter durations (up to 7 days) and lower daily quantities.per product/day and duration up to 7 days for new patients

    Examples enumerated per formulation in the document (hydromorphone, morphine, meperidine, oxycodone, PROLATE products).

    Illustrative product limits

    Examples of specific per‑day limits in document

    Hydromorphone examples: Examples in the formulary include: hydromorphone suppository 3 mg limited to 6 supps/day (experienced example); hydromorphone tablet 2 mg limited to 9 tabs/day (experienced example); hydromorphone tablet 4 mg limited to 4 tabs/day; some formulations limited to 18 mL/day.6 supps/day; 9 tabs/day; 4 tabs/day; 18 mL/day

    Multiple repeated listings across chunks reference these limits.

    Morphine and meperidine examples: Examples include morphine solution 10 mg/5 mL limited to ~24.5 mL/day (new) or 45 mL/day (experienced); meperidine solution 50 mg/5 mL limited to 49 mL/day (new) or 90 mL/day (experienced); meperidine 50 mg tablets limited to 9 or 18 tabs/day depending on experience.24.5–45 mL/day; 49–90 mL/day; 9–18 tabs/day

    See product lines for exact per‑product values.

    Quantity limit rules (new vs experienced opioid treatment)

    Quantity limits are applied based on patient opioid-treatment status and product strength/formulation.

    General quantity limit rules

    • New to treatment examples: PROLATE TAB 5‑300 MG: 6 tabs/day for up to 7 days; PROLATE TAB 7.5‑300 MG: 4 tabs/day for up to 7 days; PROLATE TAB 10‑300 MG: 3 tabs/day for up to 7 days; tramadol IR examples include 3–6 tabs/day for up to 7 days.durations up to 7 days

      Document shows multiple repeated examples

    • Experienced treatment examples: PROLATE TAB strengths commonly limited to 8–12 tabs/day; liquid opioid formulations limited to up to 30 mL/day; tramadol ER often limited to 1 tablet/day per examples.daily limits

      Document contains repeated variants across chunks

    Opioid quantity limits (new vs experienced users)

    Quantity limits apply as listed; for opioids the rules differ for patients new to opioid treatment vs experienced patients and supply is typically restricted to short durations (up to 7 days) for initial prescribing.

    Opioid short‑term prescribing limits: When prescribing certain immediate‑release opioid products for acute use, the supply is limited to up to 7 days and per‑day tablet or mL limits depend on whether the patient is new to opioid treatment or experienced (examples in document: new = lower per‑day counts such as 2–6 tabs/day or specified mL/day; experienced = higher per‑day counts such as 6–12 tabs/day or higher mL/day).up to 7 days; per‑day counts vary by product and patient status

    Examples appear throughout the opioid entries (see chunks 162–166).

    Quantity limits for listed non‑specialty medications

    Other non‑specialty medications have explicit numeric quantity limits indicated (per day, per 28/30 days, or per 365 days) usually provided adjacent to each product name.

    Non‑opioid medication quantity limits: Each listed non‑specialty medication has an associated numeric quantity limit (examples: pregabalin formulations limited to 2–3 capsules/day; VALTOCO nasal spray limited to 10–20 devices per 30 days; various antipsychotics and antidepressants limited to 1–3 tablets/units per day), and coverage is limited to the stated quantities.varies by product (see product entries)

    Providers must follow the numeric limits tied to each medication listing.

    If a medication on the Premium formulary has a listed quantity limit, coverage is limited to the stated quantity and time period. Amounts dispensed above those limits are not guaranteed to be covered; where this list differs from a member’s benefit plan, the benefit plan documents govern. Members with questions should contact their provider or the phone number on their ID card.

    The document excerpts provided do not list any explicit product exclusions. The content focuses on numeric quantity limits per product and per patient opioid‑treatment status rather than naming products that are excluded from coverage.

    Within these provided excerpts there are no explicit exclusions identified. The tables and lines presented specify per‑product quantity limits and short‑course supply restrictions but do not enumerate products that are categorically excluded from coverage.

    No explicit exclusions are listed in this excerpt; the material repeats per‑formulation quantity limits (for example, hydromorphone formulations) and maximum short‑course durations without stating non‑coverage exclusions.

    This portion of the document enumerates quantity limits by formulation and by patient opioid‑treatment status but does not include explicit coverage exclusions. It lists numeric per‑day and per‑course limits rather than products that are excluded.

    The section excerpts present repeated quantity‑limit entries (e.g., hydromorphone tabs, suppositories, and liquids) and do not state any explicit non‑coverage exclusions. The focus is on limits that apply when the medication is covered.

    No explicit non‑coverage exclusions are listed in the provided chunks. The extracted content is centered on quantity limits per product and indicates that coverage is limited to those amounts; it does not identify products that are categorically excluded from coverage in these excerpts.

    Initial Therapy (New-to-Opioid) Criteria

    Initial opioid therapy

    Initial opioid therapy limits

    New-to-opioid limits: Patients new to opioid treatment will have shorter day supplies and lower per‑day tablet or mL limits for specific products (commonly up to 7 days).examples in document: per‑day tab/mL limits for up to 7 days

    See product‑specific entries for exact numeric limits.

    Initial therapy limits

    Initial (new-to-opioid) therapy quantity caps

    Hydrocodone/acetaminophen and hydrocodone/ibuprofen examples: For new‑to‑opioid patients, common initial caps include: hydrocodone/ibuprofen 7.5/200 or 10/200 mg — 4–6 tabs/day for up to 7 days (experienced users allowed higher daily counts); hydrocodone/acetaminophen liquids — reduced mL/day for new users (examples shown across product lines).per‑day tab/mL limits; up to 7 days

    Product-Specific Quantity Limits

    albendazole
    Productalbendazole tab 200 mg
    Quantity limit120 tablets per 180 days
    Source notePremium Non‑Specialty Quantity Limit table
    BILTRICIDE
    ProductBILTRICIDE TAB 600 MG
    Quantity limit105 tablets per 180 days
    Source notePremium Non‑Specialty Quantity Limit table

    Drug Mentions and Coding Notes

    Drugs mentioned (no billing codes provided)NDC
    NDC not listedNo NDCs provided in this section; only product names and strengths are listed
    Formulary drug descriptorsNDC
    PROLATE TAB 5-300 MGCombination opioid tablet example listed with varying quantity limits
    PROLATE TAB 7.5-300 MGCombination opioid tablet example listed with varying quantity limits
    PROLATE TAB 10-300 MGCombination opioid tablet example listed with varying quantity limits
    tramadol ER tabTramadol extended-release tablet; listed limit 1 tablet/day in places and other limits elsewhere
    tramadol tab 25 mgTramadol immediate-release 25 mg tablet; various new/experienced limits listed
    Example thresholds
    ItemExamples of product limits include 56 tablets per 28 days (ZYVOX) and 3 syringes per 28 days (REPATHA)
    Most actionableRefer to the listed per‑product quantity (e.g., 56 tablets/28 days for ZYVOX) when adjudicating coverage
    SourcePremium Non‑Specialty Quantity Limit table entries

    Provider Actions, Documentation & Prior Authorization

    Note

    Quantity limits govern coverage amounts

    Quantity limits listed in the Premium formulary define the amount of a drug that will be covered (e.g., tablets per day, mL per day, per‑fill or per period). When a medication includes a quantity limit, coverage is limited to the specified amount and timeframe; quantities above the listed limit may not be covered and could require payer review.

    • Coverage limited to the specified per‑day, per‑fill, or time‑period quantity as shown in the formulary table.
    • If quantities exceed the listed limit, coverage may be denied or prior authorization may be required.
    Note

    Quantity limits govern coverage

    Coverage is managed primarily by preset quantity limits rather than explicit prior‑authorization conditions in this section; follow the formulary’s stated per‑day and per‑fill limits when prescribing.

    • Quantity limits specify daily tablets or mL and short‑course durations (commonly up to 7 days for new opioid starts).
    • When differences exist between this list and a member’s benefit plan, the benefit plan documents govern.

    Definitions and Terms

    Step Therapy Notes

    StepDescription
    1
    Quantity limit rules are based on FDA‑approved uses, medication instruction labels, and accepted clinical recommendations; this table lists per‑product quantity limits rather than specifying step‑therapy sequences.
    StepDescription
    1
    Determine whether the patient is 'new to opioid treatment' or 'experienced with opioid treatment'; this determination is used to select the applicable per‑day quantity limit (examples: PROLATE TAB 5‑300 mg = 6 tabs/day for new patients up to 7 days; experienced patients limited to 12 tabs/day).

    Background and Intent

    Quantity limits are program rules intended to reduce the risk of overuse and to align supply with safe dosing and approved indications. Limits are established using FDA‑approved uses, manufacturer labeling, and accepted clinical guidance; when a drug on the Premium formulary has a quantity limit, only the specified amount and duration will be covered unless prior authorization allows an exception.

    Revision History

    2026-07-01effective_dateLatest

    Quantity limits and formulary changes became effective; the Premium formulary quantity limits listed are effective July 1, 2026.

    Policy Summary
    PayerAmeriHealth
    PolicyQuantity limits — Premium Formulary (Premium Non‑Specialty)
    Policy CodePolicy N/A
    Change TypeRoutine update — no material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionDocument whether the patient is new to opioid treatment or experienced on prescriptions so the appropriate per-day quantity limit and short-course duration are applied.
    SourceLink
    On This Page
    Coverage Criteria and General RulesInitial Therapy (New-to-Opioid) CriteriaProduct-Specific Quantity LimitsDrug Mentions and Coding NotesProvider Actions, Documentation & Prior AuthorizationDefinitions and TermsStep Therapy NotesBackground and IntentRevision History
    10 mL/day (new), 18 mL/day (experienced)

    Liquid concentration referenced as 1 mg/mL in multiple chunks

    Hydromorphone suppositories: If new to opioid treatment: limit to 3 suppositories/day for up to 7 days; if experienced: limit to 6 suppositories/day.3 supps/day (new), 6 supps/day (experienced)

    3 vs 6 supps/day appears consistently in several chunks

    Document contains repeated, sometimes inconsistent listings

    Hydromorphone immediate‑release tablet 2 mg: Referenced under the same new/experienced user distinctions where explicit; see product lines for per‑day numeric limits.see formulation‑specific limits above

    Chunks contain partial text

    5 tabs/day (2 mg typical for new) ; ER example 2 tabs/day

    Text is repetitive and fragmented

    See chunks 72,76,81

    chunks 90,95

    Hydromorphone tablets 4 mg: Limited to 2 tablets/day for up to 7 days for new users (documented); experienced‑user limits are referenced but not consistently numeric across entries.2 tabs/day (new); experienced limit variable

    chunks 102,103,109

    2 tabs/day (new) | experienced limit variable

    chunks 108,123,126

    Hydromorphone liquid formulation: Experienced patients: limited to 18 mL/day (liquid).18 mL/day (experienced)

    chunks 108,111

    Maximum course length: Most references limit initial prescriptions to up to 7 days when new to treatment regardless of formulation.7 days

    chunks 108,110

    Exact tab or mL limits vary by product entry in the formulary.

    Hydromorphone liquid initial: New‑to‑opioid: 10 mL/day (1 mg/mL) for up to 7 days.10 mL/day; up to 7 days

    Referenced repeatedly

    Hydromorphone suppository initial: New‑to‑opioid: 3 suppositories/day for up to 7 days.3 supps/day; up to 7 days

    Appears across chunks

    Initial therapy limits

    Initial opioid therapy limits

    New to opioid treatment: New opioid users are limited to lower daily quantities and shorter duration: hydromorphone suppositories 3/day (up to 7 days), hydromorphone liquid 10 mL/day (1 mg/mL) for up to 7 days, and ER tablets commonly limited to 2/day in many entries.3 supps/day; 10 mL/day; 2 tabs/day

    Stated repeatedly

    Initial therapy quantity limits

    Initial/short-course limits based on opioid experience:

    Hydromorphone liquid (1 mg/mL): New to opioid treatment: limited to 10 mL/day for up to 7 days; Experienced: limited to 18 mL/day.10 mL/day (new), 18 mL/day (experienced)
    Hydromorphone suppository (3 mg): New to opioid treatment: limited to 3 suppositories/day for up to 7 days; Experienced: limited to 6 suppositories/day.3 supps/day (new), 6 supps/day (experienced)
    Hydromorphone tablet (2 mg): Document references a limit of 5 tablets/day for 2 mg tablets for up to 7 days; ER tablet example cited as 2 tablets/day.5 tabs/day (2 mg); ER example 2 tabs/day

    Initial therapy

    Initial opioid therapy quantity limits (short course):

    Initial (new) therapy limits: Liquid: 10 mL/day for up to 7 days; Suppositories: 3 supps/day for up to 7 days; Tablets (2 mg): 5 tabs/day for up to 7 days.see text

    chunks 72,75

    Initial therapy limits

    Short-course initial therapy limits

    Initial short-course limits: Prescriptions for patients new to opioid treatment are limited per day and to a maximum of 7 days: oral solution 10 mL/day; suppository 3 mg = 3 supps/day; tablet 2 mg = 5 tabs/day; tablet 4 mg = 2 tabs/day.

    chunks 90,99,102

    Initial therapy limits

    Initial therapy quantity rules distinguish opioid‑naïve (new) versus experienced patients:

    Suppository 3 mg initial: New to opioid treatment: up to 3 supps/day for up to 7 days; Experienced: up to 6 supps/day.
    Tablet 2 mg initial: New to opioid treatment: up to 5 tabs/day for up to 7 days; Experienced: up to 9 tabs/day.
    Tablet 4 mg initial: New to opioid treatment: up to 2 tabs/day for up to 7 days; Experienced: higher limits are variably referenced (examples include up to 4 tabs/day in some entries).

    Initial (new to opioid treatment) quantity limits

    Initial (new to opioid treatment) quantity limits

    Initial (new) limits: For patients new to opioid treatment, prescriptions are generally limited to lower per‑day quantities and typically for up to 7 days as specified per product (examples: meperidine solution 49 mL/day; meperidine tablets 9 tabs/day; morphine solution 24.5 mL/day; morphine suppositories 9 supps/day; oxycodone/acetaminophen solutions 32.6 mL/day).per product as listed; up to 7 days

    Values are product specific and appear throughout the document chunks.

    Initial therapy

    Initial (new-to-treatment) therapy quantity limits — examples provided by product strength.

    Initial therapy limits by PROLATE and tramadol examples: New‑to‑treatment patients are limited to lower daily tablet counts for up to 7 days (examples: PROLATE TAB 5‑300 MG: 6 tabs/day for up to 7 days; PROLATE TAB 7.5‑300 MG: 4 tabs/day for up to 7 days; PROLATE TAB 10‑300 MG: 3 tabs/day for up to 7 days; tramadol immediate‑release examples show 3–6 tabs/day for up to 7 days).up to 7 days

    Document repeats these examples across multiple chunks.

    Initial opioid therapy limits

    Opioid initiation limits

    Opioid initial prescribing: For patients new to opioid treatment, prescriptions are limited to short supplies (commonly up to 7 days) and lower per‑day tablet counts; experienced patients have higher allowable per‑day counts as shown per product lines.up to 7 days; per‑day tablet counts vary by product

    See opioid entries across chunks 162–166.

    ZYVOX
    ProductZYVOX TAB 600 MG
    Quantity limit56 tablets per 28 days; 1 course per 90 days
    Source notePremium Non‑Specialty Quantity Limit table (ZYVOX entries)
    REPATHA
    ProductREPATHA
    Quantity limit3 syringes per 28 days
    Source notePremium Non‑Specialty Quantity Limit table
    diclofenac patch
    Productdiclofenac patch
    Quantity limit2 patches per day up to 15 days
    Source notePremium Non‑Specialty Quantity Limit table (Analgesics Non‑Opioid)
    Liquid opioid syrups
    ProductVarious liquid opioid syrups (e.g., codeine/combination syrups)
    Quantity limit240 mL per fill, 2 fills per 60 days
    Source notePremium Non‑Specialty Quantity Limit entries for cough opioid syrups
    hydrocodone/acetaminophen combinations
    Producthydrocodone/acetaminophen combinations (various strengths/solns)
    Quantity limitProduct‑specific; examples in document show limits ranging ~73.5–180 mL/day depending on new vs experienced status and strength
    Source notePremium Non‑Specialty Quantity Limit examples for hydrocodone/acetaminophen solutions and strengths
    hydrocodone/ibuprofen
    Producthydrocodone/ibuprofen tab 7.5-200 mg; hydrocodone/ibuprofen tab 10-200 mg
    Quantity limit4–12 tablets per day (varies by strength and patient opioid‑experience status)
    Source notePremium Non‑Specialty Quantity Limit entries for hydrocodone/ibuprofen
    hydromorphone ER
    Producthydromorphone ER tab
    Quantity limitTypical limit 2 tablets/day; some entries reference up to 9 tablets/day for experienced users
    Source notePremium Non‑Specialty Quantity Limit (hydromorphone ER entries)
    hydromorphone liquid 1 mg/mL
    Producthydromorphone liquid 1 mg/mL (oral solution)
    Quantity limit10–18 mL/day (10 mL/day for patients new to opioid treatment; 18 mL/day for experienced patients)
    Source notePremium Non‑Specialty Quantity Limit entries (hydromorphone liquid)
    hydromorphone suppository 3 mg
    Producthydromorphone suppository 3 mg
    Quantity limit3–6 suppositories per day (3/day for new-to‑opioid treatment; 6/day for experienced patients)
    Source notePremium Non‑Specialty Quantity Limit entries (hydromorphone suppository)
    hydromorphone suppository (new vs experienced)
    Producthydromorphone suppository 3 mg
    Quantity limit3 suppositories/day (new) or 6 suppositories/day (experienced)
    Source noteRepeated Premium Non‑Specialty Quantity Limit entries
    hydromorphone liquid (new vs experienced)
    Producthydromorphone liquid 1 mg/mL
    Quantity limit10 mL/day (new) or 18 mL/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit repeated entries
    hydromorphone ER tablet (examples)
    Producthydromorphone ER tablet
    Quantity limitCommon example: 2 tablets/day (typical); some entries reference up to 9 tabs/day for experienced users
    Source notePremium Non‑Specialty Quantity Limit table (hydromorphone ER references)
    hydromorphone tablet 2 mg
    Producthydromorphone tablet 2 mg
    Quantity limitListed across entries; documented example limits include 5 tablets/day (new) and up to 9 tablets/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit hydromorphone tab lines
    hydromorphone liquid — new/experienced
    Producthydromorphone liquid 1 mg/mL (oral solution)
    Quantity limit10 mL/day (new) or 18 mL/day (experienced)
    Source noteDocumented repeated entries
    hydromorphone supp 3 mg (new vs experienced)
    Producthydromorphone suppository 3 mg
    Quantity limit3 supps/day (new) | 6 supps/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit table (multiple repeated chunks)
    hydromorphone tab 2 mg (documented)
    Producthydromorphone tablet 2 mg
    Quantity limit5 tabs/day (new) or up to 9 tabs/day (experienced) — 5 tabs/day documented as a new‑user example
    Source notePremium Non‑Specialty Quantity Limit repeated entries
    hydromorphone ER example
    Producthydromorphone ER tablet
    Quantity limitExample reference: 2 tablets/day
    Source notePremium Non‑Specialty Quantity Limit entries
    hydromorphone oral solution
    Producthydromorphone (oral solution) 1 mg/mL
    Quantity limit10 mL/day (new) or 18 mL/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit (oral solution lines)
    hydromorphone supp 3 mg (repeat)
    Producthydromorphone suppository 3 mg
    Quantity limit3 supps/day (new) or 6 supps/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit (hydromorphone suppository lines)
    hydromorphone tab 2 mg (new/experienced)
    Producthydromorphone tablet 2 mg
    Quantity limit5 tabs/day (new) / 9 tabs/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit entries
    hydromorphone tab 4 mg
    Producthydromorphone tablet 4 mg
    Quantity limit2 tabs/day (new); experienced‑user limit referenced (up to 4 tabs/day in some entries)
    Source notePremium Non‑Specialty Quantity Limit lines referencing 4 mg limits
    hydromorphone — maximum supply duration
    Producthydromorphone (all listed formulations)
    Quantity limitMaximum supply duration: up to 7 days for initial/short‑course prescribing
    Source notePremium Non‑Specialty Quantity Limit repeated statements about 7‑day max
    hydromorphone supp 3 mg (summary)
    Producthydromorphone suppository 3 mg
    Quantity limit3 supps/day (new) | 6 supps/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit table entries
    hydromorphone tab 2 mg (summary)
    Producthydromorphone tablet 2 mg
    Quantity limit5 tabs/day (new) | 9 tabs/day (experienced)
    Source notePremium Non‑Specialty Quantity Limit table entries
    hydromorphone tab 4 mg (summary)
    Producthydromorphone tablet 4 mg
    Quantity limit2 tabs/day (new); experienced limit referenced up to 4 tabs/day in document
    Source notePremium Non‑Specialty Quantity Limit hydromorphone 4 mg lines
    hydromorphone liquid (experienced‑user limit)
    Producthydromorphone (oral solution/liquid) — various entries
    Quantity limit18 mL/day referenced for experienced patients (document shows 10 mL/day for new users elsewhere)
    Source notePremium Non‑Specialty and Specialty Quantity Limit entries
    hydromorphone supp 3 mg (experienced)
    Producthydromorphone suppository 3 mg
    Quantity limit6 suppositories/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    hydromorphone tab 2 mg (experienced)
    Producthydromorphone tablet 2 mg
    Quantity limit9 tablets/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit table
    hydromorphone tab 4 mg (experienced)
    Producthydromorphone tablet 4 mg
    Quantity limit4 tablets/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    hydromorphone (liquid) repeated
    Producthydromorphone (liquid) — repeated entries
    Quantity limit18 mL/day cited in multiple entries
    Source notePremium Non‑Specialty Quantity Limit table
    hydromorphone supp — example
    Producthydromorphone suppository 3 mg
    Quantity limit6 suppositories/day (example) — appears in multiple entries
    Source notePremium Non‑Specialty Quantity Limit table
    hydromorphone tab 2 mg — example
    Producthydromorphone tab 2 mg
    Quantity limit9 tablets/day (example) — appears repeatedly
    Source notePremium Non‑Specialty Quantity Limit table
    hydromorphone tab 4 mg — example
    Producthydromorphone tab 4 mg
    Quantity limit4 tablets/day (example) — referenced in document
    Source notePremium Non‑Specialty Quantity Limit lines
    hydromorphone — 18 mL/day references
    Producthydromorphone (some formulations) — liquid
    Quantity limit18 mL/day cited for some formulations
    Source notePremium Non‑Specialty Quantity Limit repeated entries
    meperidine solution
    Productmeperidine soln 50 mg/5 mL
    Quantity limit49 mL/day (new‑user example)
    Source notePremium Non‑Specialty Quantity Limit (meperidine lines)
    meperidine solution (experienced)
    Productmeperidine soln 50 mg/5 mL
    Quantity limit90 mL/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit (meperidine lines)
    meperidine tab 50 mg (new)
    Productmeperidine tab 50 mg
    Quantity limit9 tablets/day (new‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    meperidine tab 50 mg (experienced)
    Productmeperidine tab 50 mg
    Quantity limit18 tablets/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    morphine solution 10 mg/5 mL
    Productmorphine soln 10 mg/5 mL
    Quantity limit24.5 mL/day (new‑user example) and 45 mL/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit (morphine solution lines)
    morphine solution (experienced)
    Productmorphine soln 10 mg/5 mL
    Quantity limit45 mL/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    morphine suppository 5 mg
    Productmorphine suppository 5 mg
    Quantity limit9 suppositories/day (new) and 18 suppositories/day (experienced) as examples in document
    Source notePremium Non‑Specialty Quantity Limit (morphine suppository lines)
    morphine supp (experienced)
    Productmorphine suppository 5 mg
    Quantity limit18 suppositories/day (experienced‑user example)
    Source notePremium Non‑Specialty Quantity Limit entries
    oxycodone/acetaminophen solution
    Productoxycodone/acetaminophen solution 5-325 mg/5 mL
    Quantity limit32.6 mL/day (new) and 60 mL/day (experienced) shown as examples
    Source notePremium Non‑Specialty Quantity Limit (oxycodone/acetaminophen solution lines)
    oxycodone caps 5 mg
    Productoxycodone caps 5 mg
    Quantity limit6 caps/day (new) or 12 caps/day (experienced) — example lines
    Source notePremium Non‑Specialty Quantity Limit entries
    PROLATE products
    ProductPROLATE solutions/tabs (various strengths)
    Quantity limitExamples: 16.3 mL/day (new) and 30 mL/day (experienced) for solutions; tab limits vary by strength
    Source notePremium Non‑Specialty Quantity Limit (PROLATE lines)
    PROLATE TAB 5-300 MG
    ProductPROLATE TAB 5-300 MG
    Quantity limit6–12 tabs/day (6 tabs/day for new patients up to 7 days; up to 12 tabs/day for experienced patients)
    Source notePremium Non‑Specialty Quantity Limit entries
    PROLATE TAB 7.5-300 MG
    ProductPROLATE TAB 7.5-300 MG
    Quantity limit4–8–12 tabs/day (4 tabs/day new up to 7 days; 8 or 12 tabs/day appear as experienced‑user examples)
    Source notePremium Non‑Specialty Quantity Limit (PROLATE 7.5 mg lines)
    PROLATE TAB 10-300 MG
    ProductPROLATE TAB 10-300 MG
    Quantity limit3–6–12 tabs/day (3 tabs/day new up to 7 days; higher limits shown for experienced users in other entries)
    Source notePremium Non‑Specialty Quantity Limit (PROLATE 10 mg lines)
    tramadol ER
    Producttramadol ER tab
    Quantity limit1 tablet per day (documented in multiple entries)
    Source notePremium Non‑Specialty Quantity Limit (tramadol ER lines)
    tramadol 25 mg
    Producttramadol tab 25 mg
    Quantity limit3–6 tablets per day (varies by product and patient opioid experience)
    Source notePremium Non‑Specialty Quantity Limit entries (tramadol IR lines)
    Note

    Quantity limits based on opioid treatment experience

    Opioid quantity limits differ depending on whether the patient is new to opioid treatment or experienced; new‑to‑treatment patients are subject to lower per‑day quantities and shorter course durations (commonly up to 7 days).

    • Examples: hydromorphone liquid (1 mg/mL) — 10 mL/day for new patients vs 18 mL/day for experienced patients.
    • Hydromorphone suppository 3 mg — 3 supps/day (new) vs 6 supps/day (experienced).
    Prior Authorization

    Quantity limits may trigger prior authorization

    Quantity limits are defined by formulation and patient opioid‑experience status; prescriptions exceeding the stated limits may require prior authorization per payer processes.

    • Standard non‑specialty per‑day limits (liquid, suppository, tablet) are listed; prior authorization may be required for amounts above those limits.
    • Some items (starter/titration packs) imply special handling when supplies differ from standard limits.
    Prior Authorization

    Prior authorization for quantities above limits

    If a prescription exceeds the formulary quantity listed for a medication or for the patient’s opioid‑experience category, submit a prior authorization with supporting documentation (medical necessity) as required by the payer.

    • Follow payer prior authorization processes when requesting quantities above the formulary limit.
    • Maintain documentation of medical necessity for override or prior‑authorization requests.
    Denial Risk

    Quantity limits enforcement

    The formulary presents enforced quantity limits by formulation and patient status; prescribers must ensure prescriptions conform to the listed per‑day and per‑course limits to avoid adjudication issues.

    • Pharmacy adjudication will reference the formulary per‑fill and period limits when determining allowed dispense quantity.
    • Amounts above the listed limits may be reduced at point of adjudication or denied.
    Prior Authorization

    Prior authorization for quantities above limits

    Requests for quantities above the listed daily or course limits for opioid formulations may be subject to prior authorization review; providers should expect review when exceeding the stated per‑day limits for the patient’s experience status.

    • Quantity limits are applied per formulation (e.g., hydromorphone tabs, suppositories, liquid) and differ for new vs experienced patients.
    • Prior authorization may be required if prescribing beyond the listed per‑day amounts or the up‑to‑7‑day initial supply.
    Note

    Quantity limits vary by patient opioid experience

    Prescribers must follow per‑product quantity limits that vary by whether the member is new to opioid treatment or experienced; determine and apply the appropriate limit for each product when submitting claims or prior‑auth requests.

    • Limits differ by product and formulation (e.g., hydromorphone tabs/supps/liquid have separate limits).
    • Use the patient’s opioid‑treatment status to select the applicable per‑day limit.
    Prior Authorization

    Prior authorization for quantities above limits

    When prescribing amounts above the formulary’s daily limits for listed products, anticipate that a prior authorization may be required and that the request must document the rationale and medical necessity.

    • Some liquid formulations and tablet strengths list higher experienced‑user limits; requests above those listed amounts may require PA.
    • The formulary and its limits are effective July 1, 2026; follow payer PA procedures for exceptions.
    Prior Authorization

    Quantity limits — prior authorization may be required

    Quantity limits are specified per medication (examples include opioid limits expressed as tablets per day or mL per day and short‑course caps up to 7 days); prescribers seeking quantities above these limits may need to submit a prior authorization per payer process.

    • Examples: many opioids limited by tabs/day for up to 7 days; other agents have per‑28/30/365‑day limits shown in the formulary.
    • If a requested quantity exceeds the listed limit, follow the prior‑authorization process and supply documentation.
    Prior Authorization

    Prior authorization implication

    Some products (e.g., starter packs or titration packs) imply special handling; prior authorization or additional review may be required when supplies differ from standard quantity limits.

    • Examples in the document reference starter or titration packs that may require special consideration.
    • Contact payer or follow PA guidance if prescribing starter/titration packs outside standard limits.
    Prior Authorization

    Prior authorization for quantities above limits

    Some requests above the stated quantity limits may require prior authorization per payer process; the formulary limits are effective July 1, 2026 and the list is subject to updates.

    • Claims exceeding listed quantity limits may be subject to denial or prior authorization review.
    • The formulary is regularly updated; verify current limits when submitting requests.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Step Therapy

    Step therapy (not specified)

    Quantity limit rules are established using FDA‑approved indications, medication labeling, and accepted clinical recommendations; the formulary does not define a step‑therapy sequence in this section.

    • Quantity limits are based on FDA uses, label instructions, and clinical guidance.
    • No explicit step‑therapy sequences are specified in this extract.
    Step Therapy

    Step therapy not specified

    No step‑therapy sequences are provided in this fragment; the policy focuses on numeric quantity limits and on determining whether a patient is 'new to opioid treatment' or 'experienced' as part of applying those limits.

    • Determination of 'new' vs 'experienced' opioid treatment functions as a step when applying quantity limits.
    • Providers should not assume step‑therapy requirements from this extract; follow separate step‑therapy policy documents if applicable.
    Note
    Denial Risk

    Coverage limited to listed quantity

    If a medication includes a quantity limit, only the specified amount will be covered; members should contact their provider or the phone number on their ID card for questions.

    • Coverage is limited to the listed quantity limits; amounts above the listed limits may not be covered.
    • Members should consult their benefit documents or contact the payer for questions.
    Documentation Required

    Document patient opioid treatment status

    Prescriptions must indicate whether the patient is new to opioid treatment or experienced so the correct per‑day limit and allowable short‑course duration (commonly up to 7 days for new starts) are applied.

    • Document opioid‑treatment status on the prescription or accompanying prior‑auth request.
    • New‑to‑treatment examples: lower per‑day limits and up to 7 days maximum supply.
    Documentation Required

    Document whether the patient is new to opioid treatment or experienced

    Prescribers should document the patient’s opioid‑treatment status (new vs experienced), the prescribed formulation, and the daily volume/number to justify that the requested quantity falls within policy limits or to support an override/PA request.

    • Include formulation (liquid/tablet/suppository), concentration or strength, and intended daily dose and duration when submitting claims or PA.
    • Maintain supporting clinical documentation when requesting quantities above listed limits.
    Documentation Required

    Patient experience status required

    Prescriptions should indicate patient opioid‑experience status because different per‑day limits apply (examples: hydromorphone liquid 10 mL/day for new vs 18 mL/day for experienced; suppositories 3 vs 6 per day).

    • Ensure prescriptions include the patient status so the pharmacy can apply the appropriate limit at adjudication.
    • Differentiate prescribing for new vs experienced opioid treatment to align with formulary limits.
    Documentation Required

    Prescriber should document opioid treatment status

    Prescribers should document opioid‑treatment status (new vs experienced) on prescriptions to determine applicable daily limits and allowable duration (initial prescriptions for new patients are commonly limited to up to 7 days).

    • Documentation supports correct adjudication and avoids denials for exceeding formulary limits.
    • If exceeding the limit, include medical necessity documentation with any PA request.
    Documentation Required

    Document patient opioid experience

    Prescriptions should state whether the patient is new to opioid treatment or experienced, because limits differ by status and formulation; this information is used by pharmacy adjudication to apply the correct per‑day limit.

    • Include new vs experienced status when submitting claims to ensure correct per‑day limit is applied.
    • Limits for new patients typically include both lower per‑day counts and a short‑course cap (up to 7 days).
    Documentation Required

    Documentation of treatment status

    Providers must adhere to the formulary’s daily tablet or liquid limits for new versus experienced opioid patients; documentation distinguishing status may be required by the plan to support coverage for the requested quantity.

    • Follow the listed per‑product daily limits (examples: PROLATE tabs limits and liquid mL/day values) based on patient status.
    • When requesting >listed limits, supply rationale and supporting documentation for PA.
    Billing Rule

    Match prescription to listed quantity limit

    Present prescriptions with dosing and intended duration consistent with the stated per‑day and per‑fill limits (for example, short opioid prescriptions are commonly limited to up to 7 days for new starts).

    • Match dispense quantity to the per‑day limit and intended days’ supply to avoid denials or reductions at adjudication.
    • If a larger supply is clinically indicated, prepare documentation to support a PA or override request.
    Billing Rule

    Documentation for dispensing

    Pharmacies will adjudicate claims against the formulary per‑fill and period quantity limits; providers should ensure the dispense request matches those limits or submit a prior authorization with supporting documentation.

    • Pharmacy adjudication may reduce or deny quantities above the listed limits at point of sale.
    • Include formulation, daily dose, and intended duration to facilitate correct dispensing.
    Documentation Required

    Documentation for override requests

    When requesting quantities above the listed limits, maintain documentation supporting medical necessity and include it with the prior authorization or appeal as required by the payer; the formulary is subject to updates.

    • Keep clinical records explaining why the higher quantity is necessary for the patient.
    • Provide detailed dosing, duration, prior treatment history, and any relevant clinical notes with PA requests.
    Denial Risk

    Coverage is limited to the listed quantity limits

    Coverage is limited to the listed quantity limits; amounts above the listed limits may not be covered and could be denied or reduced during claims adjudication.

    • If a medication includes a quantity limit, only the specified amount will be covered.
    • Claims exceeding the published limits are subject to denial or reduced quantity at point of adjudication.
    Denial Risk

    Quantity exceedance may trigger denial

    Prescriptions that exceed the listed per‑day or duration limits (for example, exceeding the new‑patient or experienced‑patient per‑day tablet or mL limits or supplies longer than the stated short‑course durations) may be denied.

    • Examples: hydromorphone limits (liquid/supps/tabs) and many opioids restricted to up to 7 days for new starts.
    • Requests above listed per‑day amounts (e.g., >10 mL/day for new liquids, >18 mL/day for experienced liquids, >3 supps/day for new users) risk denial.
    Documentation Required

    Patient opioid‑treatment status must be documented

    Prescriptions should indicate whether the patient is new to opioid treatment or experienced so adjudicators can apply the appropriate per‑day limit and short‑course policy; failure to document status may lead to application of the lower (new‑patient) limits or denial.

    • Document status on the prescription or include it in the PA request to ensure correct application of limits.
    • If status is unclear, the plan may apply the more restrictive new‑patient limits.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note